The XENERA ™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Condition: Breast Neoplasms Interventions: Drug: Xentuzumab; Drug: Placebo; Drug: Everolimus; Drug: Exemestane Sponsor: Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormones | Men | Menopause | Study | Women